Ye Haidong, Zhu Wei, Mei Lina, Lu Zhouxiang
Department of Surgery of Traditional Chinese Medicine, Zhejiang University of Traditional Chinese Medicine Affiliated Wenzhou Hospital, Wenzhou.
Department of General Surgery, The First Hospital of Huzhou.
Medicine (Baltimore). 2019 Aug;98(31):e16685. doi: 10.1097/MD.0000000000016685.
The aim of the study was to estimate the prognostic and clinicopathologic significance of miR-125a-5p in human cancers. Eligible studies were obtained from PubMed, Embase, and the Cochrane Library. Combined hazard ratios (HRs) and odds ratios (ORs) were used to evaluate the prognostic and clinicopathologic value of miR-125a-5p. In pan-cancer, high miR-125a-5p expression was associated with better overall survival (OS) (HR = 0.459, 95% confidence interval [CI]: 0.369-0.57, P < .001), and disease-free survival (HR = 0.343, 95% CI: 0.237-0.496, P < .001). Furthermore, favorable OS was also found in lung cancer (HR = 0.343, 95% CI: 0.228-0.517, P < .001) and gastric cancer (HR = 0.341, 95% CI: 0.160-0.725, P = .005) patients with high miR-125a-5p expression. Besides, high miR-125a-5p expression was correlated with early stage (OR = 0.413, 95% CI: 0.228-0.749, P = .004) and negative lymph node metastasis (OR = 0.262, 95% CI: 0.073-0.941, P = .04) in gastric cancer, and was linked with better tumor differentiation in pan-cancer (OR = 1.623, 95% CI: 1.064-2.476, P = .025) and lung cancer (OR = 2.371, 95% CI: 1.358-4.141, P = .002). In conclusion, miR-125a-5p is a tumor suppressor with prognostic and clinicopathologic values for human cancer, and miR-125a-5p overexpression predicted favorable prognosis, early stage, negative lymph node metastasis, and better tumor differentiation. More research should be conducted to test these results.
本研究旨在评估miR-125a-5p在人类癌症中的预后及临床病理意义。通过PubMed、Embase和Cochrane图书馆获取符合条件的研究。采用合并风险比（HRs）和比值比（ORs）来评估miR-125a-5p的预后及临床病理价值。在泛癌中，miR-125a-5p高表达与更好的总生存期（OS）相关（HR = 0.459，95%置信区间[CI]：0.369 - 0.57，P <.001），以及无病生存期（HR = 0.343，95% CI：0.237 - 0.496，P <.001）。此外，在miR-125a-5p高表达的肺癌患者（HR = 0.343，95% CI：0.228 - 0.517，P <.001）和胃癌患者（HR = 0.341，95% CI：0.160 - 0.725，P =.005）中也发现了较好的总生存期。此外，在胃癌中，miR-125a-5p高表达与早期阶段（OR = 0.413，95% CI：0.228 - 0.749，P =.004）和阴性淋巴结转移（OR = 0.262，95% CI：0.073 - 0.941，P =.04）相关，并且在泛癌（OR = 1.623，95% CI：1.064 - 2.476，P =.025）和肺癌（OR = 2.371，95% CI：1.358 - 4.141，P =.002）中与更好的肿瘤分化相关。总之，miR-125a-5p是一种对人类癌症具有预后及临床病理价值的肿瘤抑制因子，miR-125a-5p过表达预示着良好的预后、早期阶段、阴性淋巴结转移和更好的肿瘤分化。应开展更多研究来验证这些结果。
